Dr. Hastings is a physician-scientist with a research program that is focused on antigen processing and control of T cell-mediated responses with respect to tumor immunity and autoimmune disease. Her research expertise includes antigen processing and presentation, T cell tolerance, and regulatory T cells. Her laboratory has defined gamma-interferon-inducible lysosomal thiol reductase (GILT) as a critical enzyme involved in the MHC class II-restricted presentation of and modulation of central and peripheral tolerance to melanocyte differentiation antigens, which are important in the immune recognition of melanoma and in vitiligo pathogenesis.
Dr. Hastings is also a practicing dermatologist and has ongoing collaborations investigating the clinical significance of GILT expression in melanoma and lymphoma.
- Nguyen J, Bernert R, In K, Kang P, Sebastiao N, Hu C, Hastings KT; Gamma-interferon-inducible lysosomal thiol reductase is upregulated in human melanoma, Melanoma Research; 2016; 26(2):125-37.
- Rausch MP, Hastings KT; Diverse cellular and organismal functions of the lysosomal thiol reductase GILT, Molecular Immunology; 2015; 68(2 Pt A):124-8.
- Rausch MP, Hastings KT; An exhaustion-like phenotype constrains the activity of CD4+ T cells specific for a self and melanoma antigen, PlosOne; 2015; 10(4):e0123332.
- Phipps-Yonas H, Cui H, Sebastiao N, Brunhoeber PS, Haddock E, Deymier MJ, Klapper W, Lybarger L, Roe DJ, Hastings KT; Low GILT expression is associated with poor survival in diffuse large B-cell lymphoma, Frontiers in Immunology; 2013; 4:425.
- Phipps-Yonas H, Semik V, Hastings KT; GILT expression in B cells diminishes cathepsin S steady-state protein expression and activity, European Journal of Immunology; 2013; 43(1): 65-74.